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Abstract
Background and aims Insufficient perfusion of distal flap
areas, which may lead to partial necrosis, still represents a
challenge in reconstructive surgery. In the process of
microvascular and endothelial dysfunction, endothelins
(ETs) and their receptors may play an important role.
Therefore, the aim of the study was to investigate in a
chronic in vivo model the effect of various ET-receptor
antagonists in critically perfused flap tissue.
Materials and methods A random pattern musculocutane-
ous flap was elevated in the back of 25 C57BL/6 mice and
fixed into a dorsal skinfold chamber. Repetitive intravital
fluorescence microscopy was performed over a 10-day
observation period, assessing arteriolar diameter, arteriolar
blood flow (aBF), functional capillary density (FCD), the
area of tissue necrosis, and the development of newly
formed blood vessels. ET-receptor blockers were adminis-
trated intraperitoneally 30 min before induction of ische-
mia, as well as daily during the subsequent 4-day period,
including (1) BQ-123, a specific ET-A-receptor antagonist
(ET-A=1 mg/kg), (2) BQ-788, a selective ET-B-receptor
antagonist (ET-B=1 mg/kg), and (3) PD-142893, a nonse-
lective ET-AB-receptor antagonist (ET-AB=0.5 mg/kg).
Animals receiving saline only served as controls (n=7).
Results Despite an increase in aBF during the 10-day
observation period (day 1=1.92±0.29 nl/s; day 10=4.70±
1.64 nl/s), the flaps of saline-treated controls showed a
distinct decrease in FCD (94±12 cm/cm2). This perfusion
failure resulted in flap necrosis of 52±3%. Selective
blockade of the ET-B receptor caused a further increase in
aBF already at day 1 (2.97±0.42 nl/s), which persisted
during the following 10-day observation period (day 10=
5.74±0.69 nl/s). Accordingly, adequate FCD could be
maintained (day 10=215±8 cm/cm2; p<0.05 vs control),
resulting in a significant reduction in flap necrosis (day 10=
25±4%; p<0,05). In contrast, neither selective blockade
of the ET-A receptor nor nonselective ET-A- and ET-B-
receptor blockade were able to significantly affect aBF
when compared to controls (day 1=ET-A=1.39±0.10
nl/s; ET-AB=1.53±0.80 nl/s; n.s.). Accordingly, flap
necrosis after ET-A- and ET-AB-receptor inhibition did
not differ from that of controls (day 10=ET-A: 46±10%;
ET-AB=51±7%).
Conclusion Our data show that only selective ET-B-
receptor inhibition is capable of maintaining nutritive
perfusion and, hence, reducing necrosis in critically
perfused flap tissue. Accordingly, administration of ET-B-
receptor antagonists may be considered in the treatment of
critically perfused flaps.
Keywords Chronic ischemia . Endothelin-receptor
blockade . Intravital fluorescence microscopy .
Microcirculation . Random pattern flap
Introduction
The endothelin (ET) system plays a fundamental role in
cardiovascular regulation. Therefore, ET, a peptide pro-
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duced in endothelial cells, has been implicated in various
disease mechanisms including ischemic tissue damage in
flap surgery [1–5]. Ischemic tissue damage is one of the
most dreadful complications in flap surgery. It leads to
delayed wound healing or loss of tissue, which both may be
associated with increased morbidity, prolonged hospital
stay, and an increased frequency of reoperations.
ET is one of the most potent vasoconstrictors, acting on
both arteries and veins [6, 7]. The vasoconstrictor effect of
ET is thought to be mediated via the ET-A receptor, but also
via the ET-B receptor expressed on vascular smooth muscle
cells [8–10]. In addition, ET-B receptors have been
identified on endothelial cells and seem to have vaso-
dilative properties [11–13]. Therefore, it has been postulat-
ed that ET-related vasoconstriction is predominantly
mediated by the ET-A receptor, whereas the contribution
of ET-B receptors seems to depend on a balance between
dilative and constrictive effects.
Increased ET concentrations were found locally [4, 14–
17] but not systemically [2, 3] after surgical trauma
inflicted by flap elevation. Therefore, the administration
of ET-receptor antagonists might be ideal to improve local
flap microcirculation by vasodilation without causing
systemic hypotension, detrimental to the flap’s perfusion
pressure. ET-A- and combined ET-A- and ET-B-receptor
antagonists proved to be beneficial in the prevention of
ischemic tissue damage in acute [1] and chronic [5–15]
experimental settings. However, no direct examination of
the effect of ET-receptor blockade on the microvasculature
and, hence, the microcirculation, i.e., the target of ETs, has
been performed in these previous studies. In addition, the
relative contribution of the two receptor subtypes remains
to be determined yet.
The aim of the present study was therefore to investigate
in vivo the effect of ET-A-, ET-B-, and combined ET-A-
and ET-B-receptor blockade on the development of micro-
circulatory dysfunction and tissue necrosis using a chronic
musculocutaneous flap model. To this end, we used the
previously modified dorsal skinfold chamber that includes a
random pattern musculocutaneous flap, which develops a
50% necrosis if untreated [18].
Materials and methods
Animals All experiments were performed according to the
guiding principles for research involving animals and the
German legislation on protection of animals. The experi-
ments were approved by the local governmental animal
care committee. A total of 25 mice (C57BL/6; 12–24 weeks;
24–26 g body weight [bw]; Charles River Laboratories
GmbH; Sulzfeld, Germany) were included in the study. The
animals were housed in single cages at a room temperature
of 22–24°C and a relative humidity of 60–65% with a 12-h
day–night cycle. The animals were allowed free access to
drinking water and standard laboratory chow (Altromin,
Lage, Germany).
Anesthesia For surgery and repetitive intravital fluores-
cence microscopy, the animals were anesthetized by
intraperitoneal injection of 90 mg/kg bw ketamine hydro-
chloride (Ketavet®, Parke Davis, Freiburg, Germany) and
25 mg/kg bw xylazine hydrochloride (Rompun®, Bayer,
Leverkusen, Germany).
Flap preparation The dorsal skinfold chamber preparation
was used for the experiments [19]. Ischemia in musculocu-
taneous tissue was induced by the creation of a random
pattern flap. The inclusion of the flap into the dorsal
skinfold chamber results in necrosis of ∼50% of the distal
tissue as previously described in detail [18]. Briefly, after
depilation of the back of the animal, a random pattern flap
including skin and panniculus carnosus was elevated
perpendicular to the spine. To this end, two incisions
perpendicular to the spine were performed, thereby creating
a bipedicled flap with bilaterally transected main blood
supply. The incisions are joined 2–3 mm across the spine to
the intact backside of the skinfold to completely mobilize
the flap. Then the flap is sutured back to the surrounding
skin laterally, resulting in a rectangular, laterally based flap
measuring 15 mm in width and 11 mm in length. One of
two identical titanium frames of the window chamber is
then fixed to the skinfold. To achieve direct view onto the
deep surface of the flap, an area of ∼90 mm2—which
corresponds to the window in the titanium frame—of the
backside of the skinfold was removed. Finally the frame’s
counterpart was mounted and the observation window was
sealed with a coverglass for subsequent in vivo microscopy
[18]. Chambers (total weight ∼3 g) were well tolerated by
the animals, which showed no changes in sleeping and
feeding habits.
Intravital fluorescence microscopy For in vivo microscopic
analysis of the microcirculation, anesthetized mice were
placed on a plexiglas pad and received an intravenous
injection (retrobulbar) of 0.05 ml 5% fluorescein isothio-
cyanate (FITC)-labeled dextran (molecular weight 150,000;
Sigma-Aldrich, Taufkirchen, Germany). Subsequently, the
mice were positioned under a Zeiss Axiotech microscope
(Zeiss, Oberkocchen, Germany). The epi-illumination setup
included a 100-W mercury lamp and filter sets for blue
(450–490 nm excitation, >520 nm emission wavelength)
and ultraviolet (330–390 nm, >430 nm) light. Microscopic
images were captured by a charge-coupled device video
camera (FK6990, Pieper, Schwerte, Germany) and recorded
on video tape (Panasonic AG-7350-SVHS, Matsushita,
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Tokyo, Japan). All parameters were analyzed offline using a
computer-assisted image analysis system (Cap-Image,
Zeintl Software, Heidelberg, Germany) [20]. The micro-
scopic procedures for analysis of the microcirculation were
performed at constant room temperature of 23°C. Different
objectives (5×, NA (numerical aperture) = 0.16; 10×, 0.30,
and 20×, 0.32) were used for recordings.
Microcirculatory analysis At each observation time point,
the tissue within the window of the chamber was first
scanned using the 5× objective to determine the surface of
nonperfused, respectively necrotic tissue. The area of
necrosis, which was microscopically defined as tissue with
complete lack of perfusion, was determined planimetrically
and is given in percent of the total flap size.
Microcirculatory parameters were measured in the
perfused areas of the flap, including the proximal, central,
and distal part of the flap. For repetitive measurements of
the same vessels over the 10-day observation period, easily
identifiable branching patterns of second- or third-order
arterioles, accompanying collecting venules, and capillary
fields were selected. Using the 10× and 20× objective,
video printouts of the areas described above were made to
relocate the same vessels for repetitive measurements.
Functional capillary density (FCD, given as cm/cm2) was
defined as the length of all red blood cell (RBC)-perfused
capillaries per observation field. Arteriolar diameters (μm)
were measured perpendicularly to the vessel path. Arteri-
olar RBC velocity (μm/s) was analyzed using the line shift
method. This method is based on the measurement of the
shift (mm) of an individual intravascular gray level pattern
over time (seconds) [20]. Volumetric blood flow (nl/s) was
calculated in arterioles and venules from RBC velocity and
vessel cross-sectional area (π×r2) according to the equation
of Gross and Aroesty, i.e., Q=V×π×r2 assuming a
cylindrical vessel shape [21].
All three zones of the flap were examined under 20×
magnification for the development of signs of angiogenesis,
such as microvascular sprouting and bud formation.
ET-receptor antagonists Three ET-receptor antagonists
were used, i.e., (1) BQ-123, a specific ET-A-receptor
antagonist (1 mg/kg), (2) BQ-788, a selective ET-B-
receptor antagonist (1 mg/kg), and (3) PD-142893, a
nonselective ET-AB-receptor antagonist (0.5 mg/kg). The
antagonists were dissolved in 5% dimethyl sulfoxide. The
solution was stored at a maximum temperature of 4°C.
Experimental protocol A total of 25 animals were assigned
to four groups. In the control group (n=7), animals received
the same amount of saline at the corresponding time points
as the experimental groups (n=6 in all groups), which
received intraperitoneally an ET-A-, ET-B-, or ET-AB-
receptor blocker. The substances were first administered
30 min before surgery and then, to functionally block the
activity of ET during the progress of necrosis, every 24 h
during the following 4 days. Repetitive microscopic
observations were performed at day 1, 3, 5, 7, and 10 after
surgery. At the end of the experiments, the animals were
killed by injection of an overdose of anesthetics.
Statistical analysis All values are expressed as mean ±
standard error of the mean (SEM). For comparison between
individual time points within each group, analysis of
variance (ANOVA) for repeated measures was performed.
This was followed by the appropriate post-hoc test,
including the correction of the alpha-error according to
Bonferroni probabilities. For comparison between the
groups, ANOVA and the appropriate post-hoc test to
compensate for multiple comparisons were used (Sigma-
Stat, Jandel, San Rafael, CA). A value of p<0.05 was taken
to indicate statistical significance.
Results
Flap necrosis Macroscopic analysis of the skinfold cham-
bers at day 10 after surgery demonstrated morphological
changes of the microvasculature within the zone of
demarcation of the flaps (Fig. 1). A clear demarcation of
vital tissue from distal necrosis, separated by a hyperemic
red zone that indicates microvascular remodeling, was
found. This line of demarcation was located within the
center of the window of the chamber in controls, as well as
in animals receiving the ET-A- and ET-AB-receptor blocker
(Fig. 1a,b,d). In comparison, flaps treated with the selective
ET-B-receptor antagonist developed this zone of demarca-
tion more distally, thus presenting with reduced flap
necrosis (Fig. 1c).
Quantitative analysis confirmed that in control animals,
the initial microcirculatory perfusion failure at day 1 after
flap elevation was associated with an area of nonperfused
tissue of 44±7% (Fig. 1e). The persisting microcirculatory
dysfunction resulted in necrosis of 52±3% of the flap tissue
at day 10. Flap necrosis of animals pretreated with ET-A-
and ET-AB-receptor antagonists did not differ from that
observed in controls. In contrast, the administration of the
ET-B-receptor blocker showed already at day 1 a markedly
reduced microcirculatory perfusion failure (35±7% vs
control=44±7%), which resulted in a significantly im-
proved flap survival at the end of the 10-day observation
period (25±4%; p<0.05 vs control; Fig. 1e).
Arteriolar perfusion In controls, analysis of the diameter of
perfused arterioles of the flaps showed a ∼25% dilation
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from day 1 to 10 after flap elevation. Treatment with the
ET-A- and ET-AB-receptor blockers showed a slightly
increased arteriolar diameter compared to controls at day 1
after flap creation and a comparable dilation until day 10
(Fig. 2). In contrast, ET-B-receptor antagonist-treated flaps
showed significantly increased arteriolar diameters com-
pared to controls at day 1 and a ∼40% further dilation until
day 10 (Fig. 2). Accordingly, arteriolar blood flow (aBF)
was found to have increased during the first days after flap
elevation by 1.5- to 2-fold after blockade of the ET-B
receptor when compared with controls and flaps treated
with ET-A- and ET-AB-receptor antagonists (Table 1).
Capillary perfusion In control animals, FCD was found
reduced already at day 1 after flap elevation (149±12
cm/cm2) and further decreased during the 10-day observa-
tion period (94±12 cm/cm2, Figs. 3 and 4). ET-A- and ET-
AB-receptor antagonist treatment could not improve
capillary perfusion at day 1. However, the decrease in
FCD during the following 10 days was less pronounced,
resulting in slightly but significantly higher capillary
density values compared to controls at day 7 and 10,
respectively (Figs. 3 and 4). In contrast, ET-B-receptor
antagonist blockade was effective to significantly protect
capillary perfusion compared to controls already at day 1
(199±7 cm/cm2; p<0.05) and to maintain this protection of
nutritive perfusion over the entire 10-day observation
period (215±8 cm/cm2; p<0.05; Figs. 3 and 4).
Venular perfusion In all groups studied, venular blood flow
(vBF) showed a progressive increase in perfusion during
the 10-day observation period. However, flaps treated with
the ET-B-receptor antagonist presented a massive venular
outflow already at day 1, whereas ET-A- and ET-AB-
Fig. 1 Chamber tissue at day 10 after flap elevation. Sham-operated
animals (a) and mice treated with the ET-A- (b) and the ET-AB-
receptor antagonist (d) show a distinct area of demarcation including a
red zone that indicates a hyperemic response and microvascular
remodeling (arrows), separating surviving proximal tissue from distal
necrosis (asterisk) (a). Flaps receiving the ET-B-receptor blocker
develop this zone of demarcation more distally, indicating increased
flap survival (c). Magnification 16×. Quantitative analysis of the area
of necrosis (e), given in percent of the total flap area, confirmed
significant protection from flap necrosis after ET-B-receptor antago-
nist treatment (black circles) when compared to controls (white
squares) and flaps treated with the ET-A- (white circles) and the ET-
AB-receptor antagonists (gray circles). Mean ± SEM; *p<0.05 vs
control, #p<0.05 vs ET-A-receptor antagonist; §p<0.05 vs ET-AB-
receptor antagonist
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Fig. 2 Arteriolar diameters over the 10-day observation period within
perfused arterioles of control flaps (white squares), as well as flaps
treated with the ET-A- (white circles), the ET-B- (black circles), and
the ET-AB-receptor antagonists (gray circles). Only flaps pretreated
with ET-B-receptor antagonist revealed a significantly increased
arteriolar dilation when compared to controls already at day 1. Over
the 10-day observation period, the dilation response of ∼40% was
more pronounced in these animals when compared with controls as
well as the ET-A- and ET-AB-receptor antagonist pretreated animals.
Mean ± SEM; *p<0.05 vs control; &p<0.05 vs day 1
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receptor blockade induced a significant increase in vBF
only from day 7 onwards (Table 2).
Angiogenesis In vivo microscopic imaging during the
10-day observation period did not display any morphologic
changes associated with angiogenesis, such as vascular
sprouting or bud formation, neither within the zone of
demarcation, nor within the well-perfused proximal area of
the flaps (Fig. 3).
Discussion
The major finding of the present study is that the
administration of the selective ET-B-receptor antagonist
BQ-788 significantly protected from flap necrosis, whereas
the specific ET-A- (BQ-123) and the nonselective ET-AB-
receptor (PD-142893) antagonists were not capable of
influencing the manifestation of necrosis when compared
with controls. Of interest, blockade of the ET-B receptor
protected from nutritive perfusion failure already at day 1
after flap creation, and only ET-B-receptor inhibition could
further reduce the amount of the nonperfused and necrotic
tissue. In all other groups, the initially nonperfused area of
the flap finally also developed necrosis. This finding
emphasizes the importance of early intervention in con-
ditions of critical ischemia.
Because ET is one of the most potent vasoconstrictors,
administration of receptor antagonists should result in
vasodilation within the microcirculation. In the present
study, however, there was no significant vasodilation after
blockade of ET receptors when compared to controls except
in ET-B-receptor-blocked animals, and no significant differ-
ence occurred among the study groups. Over the 10-day
observation period, there was a trend towards dilation of
Table 1 Individual volumetric blood flow (nl/s) of perfused arterioles of the flaps at day 1, 3, 5, 7, and 10 after flap elevation
Group 1 days 3 days 5 days 7 days 10 days
Control 1.92±0.29 2.81±0.70 3.58±0.23 3.81±0.22 4.70±1.64
ET-A-RA 1.39±0.08 3.07±0.49 2.16±0.42 4.60±0.54* 5.76±0.61*
ET-B-RA 2.97±0.42 4.22±0.77 4.04±0.27 7.10±1.45 5.74±0.69
ET-AB-RA 1.53±0.75 1.74±1.06 3.33±0.63 4.06±0.79* 5.89±0.29*
Control (saline-treated flaps); ET-A-, ET-B-, and ET-AB-receptor antagonist (RA)-treated flaps. Values are means ± SEM
*p<0,05 vs day 1
Fig. 3 Intravital fluorescence
microscopy of capillary perfu-
sion in the zone of demarcation
of saline-treated controls (a) and
animals treated with with ET-A-
(b), the ET-B- (c), and the ET-
AB-receptor antagonist (d).
Note the maintained functional
perfusion in capillaries pre-
treated with ET-B-receptor an-
tagonist (c), whereas nutritive
perfusion of capillaries was sig-
nificantly decreased in the other
groups (a, b, d), particularly in
untreated animals (a, arrow
heads) and mice receiving the
ET-A-receptor antagonist (b). Of
interest, no signs of angiogene-
sis, such as capillary budding
and sprouting, were observed in
either of the groups during the
10-day observation period.
Contrast enhancement was
achieved by FITC–dextran
150,000 administrated intrave-
nously. Magnification 80×
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arterioles and venules within the viable area of the flaps in
all animals. This might rather be due to hypoxia, which is
also a vasodilatory stimulus, or mechanisms of flow
redistribution after flap elevation than due to the blockade
of the ET system, because this tendency was also observed
in critically ischemic tissue in controls.
The influence of ET receptor antagonists on aBF reflects
the findings about arteriolar diameter to a certain extent
with a generalized increase in blood flow over the
observation period in all groups. After ET-B-receptor
blockade, aBF at day 1 was approximately increased
twofold when compared to the other study groups. This
difference persisted for the first 7 days, whereas arteriolar
flow in the other groups recovered only later. Accordingly,
only after ET-B-receptor blockade capillary perfusion was
found improved during the first days after flap elevation. In
fact, the values of FCD after ET-B-receptor blockade were
in the range of the physiologic values of intact tissue within
dorsal skinfold chamber preparations [18, 22]. Assessment
of FCD after blockade of the ET-A receptor or both the ET-
A and ET-B receptor revealed that the late recovery of aBF
was not anymore capable of improving capillary perfusion.
At this late time point, the nonperfused area is most
probably already beyond the possibilities of repair and
destined to necrosis.
The present study also showed a more than twofold
elevated venular drainage after ET-B-receptor blockade
when compared to the other study groups at day 1. In
general, the course of venous outflow paralleled the
findings on the arteriolar site. In contrast to the results
obtained in pigs, in which a combined ET-AB blockade in
musculocutaneous flaps attenuated only venous congestion
but not the microcirculation [1], improved microcirculatory
values were found at all levels in the present study,
including the arteriolar inflow, the capillary perfusion, and
the venous outflow. This difference might be explained by
the fact that laser Doppler flowmetry but not direct
intravital microscopy was used to assess the microcircula-
tion in the previously performed studies. Because venous
hypertension is more detrimental to flap survival than
arterial insufficiency [23] and venules show an increased
constriction upon ET [7, 24], it might be argued that
improvements found in venules are more important or are
established more rapidly in the course of the experiment
than changes in arteriolar and capillary perfusion. However,
the design of the study was not intended to solve this issue.
Besides venous dilation, an additional potential mechanism
is a possible anti-inflammatory property of ET [25] with a
decrease in leukocyte–endothelium interaction and conse-
quent improvement of rheologic conditions in the flap.
The finding that only ET-B-receptor blockade improves
flap survival is somewhat intriguing. Previous studies have
shown a benefit of an ET-A-receptor antagonist in rats [5,
15] and a nonselective combined ET-receptor antagonist in
pigs [1]. However, no comparison with ET-B-receptor
antagonists were preformed in those experiments. Thus,
our data do not allow us to draw conclusions about the
reasons for the differences observed in response to
blockade of the two receptor subtypes. Nevertheless, one
can speculate that a difference exists in receptor affinity and
half-time of the blocker used. Furthermore, the literature is
Table 2 Individual volumetric blood flow (nl/s) of perfused venules of the flaps at day 1, 3, 5, 7, and 10 after flap elevation
Group 1 days 3 days 5 days 7 days 10 days
Control 2.84±0.39 3.92±0.12 4.73±0.54 7.79±1.26* 6.84±2.35*
ET-A-RA 1.21±0.46 3.60±0.59 3.68±0.17 9.35±2.00* 8.61±2.89*
ET-B-RA 4.76±0.49 6.24±1.64 6.84±0.78 8.87±0.77 11.37±0.47
ET-AB-RA 2.00±0.98 3.47±1.89 5.37±2.27 7.78±3.21 12.10±2.42*
Control (saline-treated flaps); ET-A-, ET-B-, and ET-AB-receptor antagonist (RA)-treated flaps. Values are means ± SEM
*p<0,05 vs day 1
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Fig. 4 Functional capillary density (FCD) over the 10-day observa-
tion period within perfused capillaries of control flaps (white squares),
as well as of flaps treated with the ET-A- (white circles), the ET-B-
(black circles), and the ET-AB-receptor antagonist (gray circles). Note
the significantly higher FCD over the entire observation period in
animals receiving the ET-B-receptor antagonist when compared to
saline-treated controls. In contrast, ET-AB- and, in particular, ET-A-
receptor blockade was not effective to significantly improve nutritive
capillary perfusion. Mean ± SEM; *p<0.05 vs control; &p<0.05 vs
day 1
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controversial about the mechanism of ET-B receptors,
which were almost exclusively identified on smooth muscle
cells and endothelial cells, causing constriction and dilation
[26]. In addition, it should be noted that there is a
pronounced heterogeneity among species, organs, and
vascular units with respect to both the distribution of
receptors and the response to ET [27].
Another finding is that no signs of angiogenesis were
observed during the entire observation period of 10 days.
ET has been implicated in tumor angiogenesis [28] and ET-
receptor antagonists therefore might have abolished all
stimuli of angiogenesis. However, because there was also a
lack of angiogenesis in the controls, this view cannot be
substantiated by the results of the present study. The major
stimulus for angiogenesis, i.e., hypoxia, is present in the
vicinity of the zone of demarcation. The absence of signs of
angiogenesis, which should be visible after ∼day 3, might
be due to desiccation of the tissue within the chamber. The
transitory zone of demarcation between the perfused area of
the flap proximally and the necrotic area distally adjacent
revealed an increased microvascular stasis, arterio-venular
dilation, and hence tortuosity but no signs of angiogenesis,
representing a zone of compromised blood perfusion as
previously shown [22].
Conclusion
The present study demonstrates the role of ET in the
pathophysiology of chronic ischemia in randomly perfused
flap tissue. ET-B-receptor blockade using the ET antagonist
BQ-788 increases tissue survival significantly that, if
untreated, suffers from ∼50% necrosis. This is attributed
to an increased arteriolar, capillary, and venous perfusion
beginning already at day 1 after flap elevation. On the other
hand, normalized blood flow values in groups treated with
ET-A- and combined ET-AB-receptor blockers were found
only at 5–7 days after flap elevation, which is too late to
prevent necrosis in the distal flap tissue.
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